Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

British Journal of Ophthalmology

Volumn 98, Issue 9, 2014, Pages 1144-1167

  Schmidt Erfurth, Ursula ^a   Chong, Victor ^b   Loewenstein, Anat ^c   Larsen, Michael ^d   Souied, Eric ^e   Schlingemann, Reinier ^f   Eldem, Bora ^g   Monés, Jordi ^h   Richard, Gisbert ⁱ   Bandello, Francesco ^j  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b OXFORD EYE HOSPITAL   (United Kingdom)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Hospital Intercommunal de Creteil   (France)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g HACETTEPE UNIVERSITY   (Turkey)

^h CENTRO MÉDICO TEKNON   (Spain)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALTEPLASE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VERTEPORFIN;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; ARTERY EMBOLISM; ARTERY THROMBOSIS; BRACHYTHERAPY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DIAGNOSTIC PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENDOPHTHALMITIS; EPIMACULAR BRACHYTHERAPY; EUROPE; EVIDENCE BASED PRACTICE; EYE INFLAMMATION; GASTROINTESTINAL DISEASE; HEALTH CARE MANAGEMENT; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; LASER COAGULATION; LENS DISEASE; LENS INJURY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SINGLE DRUG DOSE; SUBMACULAR HEMORRHAGE; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VITRECTOMY;

RETINA;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; EVIDENCE-BASED MEDICINE; HUMANS; LIGHT COAGULATION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84906690121     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305702     Document Type: Review

References (152)

1. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108:697-704. (Pubitemid 32238465)
2. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010;117:921-7.
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72. (Pubitemid 38456293)
4. Seddon JM, Willett WC, Speizer FE, et al. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996;276:1141-6. (Pubitemid 26329740)
5. Seddon JM, Cote J, Davis N, et al. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003;121:785-92. (Pubitemid 36676214)
6. Klein R, Li X, Kuo JZ, et al. Associations of candidate genes to age-related macular degeneration among racial/ethnic groups in the multi-ethnic study of atherosclerosis. Am J Ophthalmol 2013;156:1010-20 e1.
7. Gemmy Cheung CM, Li X, Cheng CY, et al. Prevalence and risk factors for age-related macular degeneration in Indians: a comparative study in Singapore and India. Am J Ophthalmol 2013;155:764-73, 73 e1-3.
8. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96.
9. Miskala PH, Bass EB, Bressler NM, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology 2004;111:1981-92.
10. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135-44. (Pubitemid 30641731)
11. Krzystolik MG, Afshari MA, Adamis AP, et al . Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46. (Pubitemid 34250056)
12. Ferrara N, Mass RD, Campa C, et al. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007;58:491-504. (Pubitemid 46706529)
13. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
14. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
15. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 2009;127:533-40.
16. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-9. (Pubitemid 350106676)
17. Campbell JP, Bressler SB, Bressler NM. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 2012;130:794-5.
18. Frennesson C, Nilsson UL, Peebo BB, et al. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmol 2010;88:420-5.
19. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol 2012;153:209-13 e2.
20. van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449-69.
21. Day S, Acquah K, Lee PP, et al. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol 2011;152:1014-20.
22. Hawkes N. Avastin is as effective as Lucentis for wet AMD and could save NHS 84 m pound a year, study shows. BMJ 2012;344:e3275.
23. Holekamp NM, Liu Y, Yeh WS, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol 2014;157:825-33 e1.
24. Krause L, Yousif T, Pohl K. An epidemiological study of neovascular age-related macular degeneration in Germany. Curr Med Res Opin 2013;29:1391-7.
25. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9.
26. Do DV. Detection of new-onset choroidal neovascularization. Curr Opin Ophthalmol 2013;24:244-7.
27. Chew EY, Clemons TE, Bressler SB, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 2014;121:535-44.
28. Segal O, Ferencz JR, Cohen P, et al. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. Isr Med Assoc J 2013;15:352-5.
29. Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology 2014;121:1102-8.
30. Gess AJ, Fung AE, Rodriguez JG. Imaging in neovascular age-related macular degeneration. Semin Ophthalmol 2011;26:225-33.
31. Ha SO, Kim DY, Sohn CH, et al. Anaphylaxis caused by intravenous fluorescein: clinical characteristics and review of literature. Intern Emerg Med 2014;9:325-30.
32. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-9.
33. Tran TH, Querques G, Forzy G, et al. Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2011;42:498-508.
34. Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118:523-30.
35. Koh AH, Chen LJ, Chen SJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013;33:686-716.
36. Parravano M, Pilotto E, Musicco I, et al. Reproducibility of fluorescein and indocyanine green angiographic assessment for RAP diagnosis: a multicenter study. Eur J Ophthalmol 2012;22:598-606.
37. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2012;32(Suppl 1):416-34.
38. Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology 2010;117:1376-80.
39. Malamos P, Sacu S, Georgopoulos M, et al. Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration. Invest Ophthalmol Vis Sci 2009;50:4926-33.
40. Sadda SR, Liakopoulos S, Keane PA, et al. Relationship between angiographic and optical coherence tomographic (OCT) parameters for quantifying choroidal neovascular lesions. Graefes Arch Clin Exp Ophthalmol 2010;248:175-84.
41. Mathew R, Pefkianaki M, Kopsachilis N, et al. Correlation of fundus fluorescein angiography and spectral-domain optical coherence tomography in identification of membrane subtypes in neovascular age-related macular degeneration. Ophthalmologica 2014;231:153-9.
42. Sander B. Optical coherence tomography in ophthalmology: an overview. Acta Ophthalmol 2009;87:245-6.
43. Keane PA, Patel PJ, Liakopoulos S, et al. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol 2012;57:389-414.
44. Giani A, Pellegrini M, Invernizzi A, et al. Aligning scan locations from consecutive spectral-domain optical coherence tomography examinations: a comparison among different strategies. Invest Ophthalmol Vis Sci 2012;53:7637-43.
45. Choma M, Sarunic M, Yang C, et al. Sensitivity advantage of swept source and Fourier domain optical coherence tomography. Opt Express 2003;11:2183-9.
46. Coscas F, Querques G, Forte R, et al. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections. Retina 2012;32:1069-76.
47. Querques G, Atmani K, Berboucha E, et al. Angiographic analysis of retinal-choroidal anastomosis by confocal scanning laser ophthalmoscopy technology and corresponding (eye-tracked) spectral-domain optical coherence tomography. Retina 2010;30:222-34.
48. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
49. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71.
50. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9.
51. Patel PJ, Tufail A. Optimizing individualized therapy with bevacizumab for neovascular age-related macular degeneration. Retina 2012. Published Online First. doi:10.1097/IAE.0b013e31823f0ba3
52. Kiss CG, Geitzenauer W, Simader C, et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50:2376-83.
53. Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 2014;121:1237-45.
54. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
55. Busbee BG, Ho AC, Brown DM, et al . Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56.
56. Schmidt-Erfurth U, Waldstein S, Deak GG, et al. A paradigm shift in the management of age-related macular degeneration: The role of biomarkers in antiangiogenic therapy. 2014.
57. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:3115-20.
58. Kashani AH, Keane PA, Dustin L, et al. Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci 2009;50:3366-73.
59. Golbaz I, Ahlers C, Stock G, et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011;52:1599-605.
60. Querques G, Forte R, Berboucha E, et al. Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmic Res 2011;46:152-9.
61. Amissah-Arthur KN, Panneerselvam S, Narendran N, et al. Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration. Eye (Lond) 2012;26:394-9.
62. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
63. Moshfeghi AA, Puliafito CA. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2005;14:671-82. (Pubitemid 40790287)
64. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16. (Pubitemid 40051904)
65. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508 e1-25.
66. Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007;85:486-94. (Pubitemid 47163109)
67. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-81. (Pubitemid 29527672)
68. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-16. (Pubitemid 40489924)
69. Gaudreault J, Fei D, Rusit J, et al . Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33. (Pubitemid 40270359)
70. Zayit-Soudry S, Zemel E, Loewenstein A, et al. Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes. Retina 2010;30:671-81.
71. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65 e5.
72. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-56 e4.
73. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
74. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
75. Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013;120:130-9.
76. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-83.
77. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42. (Pubitemid 44748725)
78. Abedi F, Wickremasinghe S, Islam AF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a Treat-and-Extend Protocol Over 2 Years. Retina 2014;34:1531-8.
79. Cilley JC, Barfi K, Benson AB III, et al. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2007;7:739-49. (Pubitemid 46707194)
80. Stefanadis C, Synetos A, Tousoulis D, et al. Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer. Int J Cardiol 2012;154:341-4.
81. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32:434-57.
82. Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215-18.
83. Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012;90:e25-30.
84. Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013;97:454-9.
85. Stein JD, Newman-Casey PA, Mrinalini T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121:936-45.
86. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5. (Pubitemid 41073112)
87. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72 e5.
88. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 2007;245:651-5. (Pubitemid 46951230)
89. Gonzalez S, Rosenfeld PJ, Stewart MW, et al. Avastin doesn't blind people, people blind people. Am J Ophthalmol 2012;153:196-203 e1.
90. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662-8.
91. Johnson D, Sharma S. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration. Curr Opin Ophthalmol 2013;24:205-12.
92. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
93. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
94. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-9.
95. Winnik S, Lohmann C, Siciliani G, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis-implications for cardiovascular safety. Int J Cardiol 2013;168:2453-61.
96. Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 2014;98(Suppl 1):i7-10.
97. Schmucker C, Ehlken C, Agostini HT, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS ONE 2012;7:e42701.
98. Jansen RM. The off-label use of medication: the latest on the Avastin-Lucentis debacle. Med Law 2013;32:65-77.
99. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8. (Pubitemid 34920936)
100. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-8. (Pubitemid 351684178)
101. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trp-eye) in human eyes? Calculations with a mathematical model. Eye Rep 2011;1:e5.
102. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85.
103. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 2011;408:276-81.
104. Saishin Y, Takahashi K, Lima e Silva R, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195:241-8. (Pubitemid 36384298)
105. Cao J, Zhao L, Li Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci 2010;51:6009-17.
106. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52. (Pubitemid 38821812)
107. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522 e1-22 e14.
108. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8 e1.
109. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118:1098-106.
110. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.
111. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201.
112. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013;33:1605-12.
113. Cho H, Shah CP, Weber M, et al. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013;97:1032-5.
114. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013;156:29-35 e2.
115. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104:694-701.
116. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-18.
117. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982;94:762-73. (Pubitemid 13203669)
118. Coscas G, Soubrane G. [Argon laser photocoagulation of subretinal neovascularization in senile macular degeneration. Results of a randomized study of 60 cases]. Bull Mem Soc Fr Ophtalmol 1982;94:149-54.
119. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1109-14.
120. Bennett SR, Folk JC, Blodi CF, et al. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990;109:33-7. (Pubitemid 20026485)
121. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1220-31.
122. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207. (Pubitemid 32147926)
123. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
124. Kaiser PK. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin 2009;25:1853-60.
125. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012;119:1001-10.
126. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012;119:992-1000.
127. Tozer K, Roller AB, Chong LP, et al. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 2013;120:2029-34.
128. Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013;120:317-27.
129. Dugel PU, Petrarca R, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. Ophthalmology 2012;119:1425-31.
130. Silva RA, Moshfeghi AA, Kaiser PK, et al. Radiation treatment for age-related macular degeneration. Semin Ophthalmol 2011;26:121-30.
131. Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol 2011;5:57-63.
132. Moshfeghi AA, Morales-Canton V, Quiroz-Mercado H, et al. 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy. Br J Ophthalmol 2012;96:1320-4.
133. Jackson TL. Radiation for CNV: CABERNET/MERITAGE/INTREPID. 2012.
134. Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol 1997;42:195-213. (Pubitemid 27509825)
135. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007;144:886-92.
136. Avery RL, Fekrat S, Hawkins BS, et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996;16:183-9. (Pubitemid 26190846)
137. Kuhli-Hattenbach C, Fischer IB, Schalnus R, et al. Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. Am J Ophthalmol 2010;149:316-21 e1.
138. Shultz RW, Bakri SJ. Treatment for submacular hemorrhage associated with neovascular age-related macular degeneration. Semin Ophthalmol 2011;26:361-71.
139. Ohji M, Saito Y, Hayashi A, et al. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998;116:1326-32. (Pubitemid 28473837)
140. Gopalakrishan M, Giridhar A, Bhat S, et al. Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection. Retina 2007;27:329-34. (Pubitemid 46402867)
141. Hattenbach LO, Klais C, Koch FH, et al. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology 2001;108:1485-92. (Pubitemid 32709042)
142. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999;106:1900-6; discussion 06-7.
143. Chen CY, Hooper C, Chiu D, et al. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina 2007;27:321-8. (Pubitemid 46398897)
144. de Juan E Jr, Machemer R. Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol 1988;105:25-9. (Pubitemid 18021339)
145. Peyman GA, Nelson NC Jr, Alturki W, et al. Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg 1991;22:575-82.
146. Ibanez HE, Williams DF, Thomas MA, et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol 1995;113:62-9.
147. Haupert CL, McCuen BW II, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 2001;131:208-15. (Pubitemid 32157035)
148. Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 2004;111:1993-2006.
149. Oshima Y, Ohji M, Tano Y. Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage. Br J Ophthalmol 2007;91:193-8. (Pubitemid 46202868)
150. Fine HF, Iranmanesh R, Del Priore LV, et al. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina 2010;30:1588-94.
151. Treumer F, Klatt C, Roider J, et al. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol 2010;94:48-53.
152. Arias L, Mones J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clin Ophthalmol 2010;4:67-72.